tirzepatide obesity nejm New in the January 30, 2025, issue of NEJM: for Heart Failure and (SUMMIT trial) https://nej.md/4hRGaTY Continuation of Oral Anticoagulation during TAVI (POPular PAUSE TAVI trial) https://nej.md/3XllHys Lentiviral Gene Therapy Study sees potential benefits of

Our medical program consist of many unique benefits which include One month of weight loss injections An initial consultation with a physician A 3 week check in call with a physician Concierge medicine through our HIPPA text messaging line A consultation with our medical director is required to discuss side effects, risks, and determine candidacy

Preliminary human research suggests that tirzepatide may enhance insulin sensitivity more efficiently than selective GLP-1 receptor agonists, challenging the notion that weight loss is the sole contributor to improved insulin sensitivity

Post-acne marks and lingering redness 2

Medical supervision and Safety